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Edited by Varda RotterAbstract Male germ cell apoptosis has been extensively
explored in rodents. In contrast, very little is known about the
susceptibility of developing germ cells to apoptosis in response to
busulfan treatment. Spontaneous apoptosis of germ cells is rarely
observed in the adult mouse testis, but under the experimental
conditions described here, busulfan-treated mice exhibited a
marked increase in apoptosis and a decrease in testis weight.
TdT-mediated dUTP-X nicked end labeling analysis indicates
that at one week following busulfan treatment, apoptosis was
conﬁned mainly to spermatogonia, with lesser eﬀects on
spermatocytes. The percentage of apoptosis-positive tubules
and the apoptotic cell index increased in a time-dependent
manner. An immediate eﬀect was observed in spermatogonia
within one week of treatment, and in the following week,
secondary eﬀects were observed in spermatocytes. RT-PCR
analysis showed that expression of the spermatogonia-speciﬁc
markers c-kit and Stra 8 was reduced but that Gli I gene
expression remained constant, which is indicative of primary
apoptosis of diﬀerentiating type A spermatogonia. Three and
four weeks after busulfan treatment, RAD51 and FasL expres-
sion decreased to nearly undetectable levels, indicating that
meiotic spematocytes and post-meiotic cells, respectively, were
lost. The period of germ cell depletion did not coincide with
increased p53 or Fas/FasL expression in the busulfan-treated
testis, although p110Rb phosphorylation and PCNA expression
were inhibited. These data suggest that increased depletion of
male germ cells in the busulfan-treated mouse is mediated by loss
of c-kit/SCF signaling but not by p53- or Fas/FasL-dependent
mechanisms. Spermatogonial stem cells may be protected from
cell death by modulating cell cycle signaling such that E2F-
dependent protein expression, which is critical for G1 phase
progression, is inhibited.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Germ cell apoptosis can be induced by pathological condi-
tions such as heat stress, exposure to ionizing radiation or
toxic substances, hormonal depletion, and loss of stem cell
factor signaling [1–6]. Busulfan is used for the treatment of
ovarian cancer and chronic myeloid leukemia [7]. However, in
the mouse and rat testis, busulfan treatment results in marked
spermatogenic cell death, with the exception of a small sub-
population of cells attached to the basal membrane of the
seminiferous epithelium. The busulfan-induced depletion of
spermatogenic germ cells is reversible and animals generally
regain fertility, albeit to varying degrees, following the active
re-proliferation of surviving germ cells [8–13]. Therefore, bu-
sulfan is also commonly used to examine spermatogonial stem
cell function and to prepare a recipient testis for germ cell
transplantation during treatment for male infertility.
Apoptotic signaling during male germ cell loss has been
demonstrated for a limited number of genes, including Fas/
FasL and p53. The Fas system is a well-known apoptotic
signal transduction pathway in which a ligand–receptor in-
teraction triggers the cell death pathway [14,15]. Previous
studies reported the spontaneous apoptosis of testis germ cells
in BALB/c and lpr/lpr mice [16,17]. Since lpr/lpr mice are de-
ﬁcient in Fas, these results indicate that Fas is not involved in
spontaneous germ cell apoptosis, although it may be partially
involved in cryptorchidism-induced apoptosis [17]. Further-
more, the tumor suppressor protein p53 is known to be in-
volved in apoptosis in the testis [18,19], and the expression of
p53 mRNA and protein in primary spermatocytes suggests
that p53 plays a role in meiotic prophase. In irradiated testes,
the expression of p53 is enhanced not only in spermatocytes
but also in spermatogonia [5,20]. These results suggest that p53
is important in the regulation of apoptosis in spermatocytes
and spermatogonia.
Chemotherapeutic drugs such as procarbazine and other
alkylating agents produce prolonged and sometimes irrevers-
ible azoospermia in humans [21]. Chemotherapy with alky-
lating agents may trigger several cellular mechanisms in bothblished by Elsevier B.V. All rights reserved.
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the transfer of the alkyl group(s) to various cellular constitu-
ents; however, DNA alkylation events within the nucleus
probably constitute the major provocations that lead to cell
death [22]. A previous study reported that round spermatids
are highly sensitive to alkylating agents such as cyclophos-
phamide [23], but a repeat of this study using quantitative RT-
PCR failed to demonstrate their hypersensitivity to alkylating
agents. Since the precise molecular target of alkylating agents
diﬀers according to their chemical structure, it is possible that
the biological eﬀects and target(s) of busulfan are diﬀerent
from those of cyclophosphamide. Indeed, the mechanisms by
which apoptosis is induced in male germ cells after chemo-
therapy are not fully understood. Following busulfan treat-
ment, spermatogonial stem cells do not die, suggesting that
they harbor factors for resistance to stressful stimuli. Thus, the
purpose of this study was to deﬁne which cell types are more
sensitive to stress induced by busulfan treatment and to in-
vestigate the molecular mechanism of cell death suppression in
spermatogonial stem cells following busulfan treatment.2. Materials and methods
2.1. Animals and busulfan treatment
One hundred twenty ICR male mice ranging in age from 8 to 12
weeks (30–40 g) were used. Eight-week-old ICR male mice received a
single intraperitoneal injection of busulfan (40 mg/kg body weight)
diluted in sesame oil as previously described [10,11]. The mice were
housed in wire cages at 22 1 C under a 12-h light–dark cycle with
70% humidity and fed ad libitum. Animals were maintained and ex-
periments were conducted in accordance with the Gyeongsang Na-
tional University Guide for the Care and Use of Laboratory Animals.
2.2. TUNEL assay (TdT-mediated dUTP-X nicked end labeling)
Testes were ﬁxed in 4% (w/v) paraformaldehyde in 0.01 M PBS (pH
7.4), washed in PBS, dehydrated in ethanol (70%, 90%, and 100%) and
embedded in paraﬃn wax. Testicular sections (5 lm) were rehydrated
(xylene 5 min; ethanol 100%, 95%, 70%, 2 min each) and washed in
distilled water prior to TUNEL staining. The sections were incubated
for 15 min with proteinase K (20 lg/mL) at room temperature and
washed with PBS (1·), and endogenous peroxidase activity was
blocked with 2% H2O2 for 5 min. Sections were re-washed three times
with PBS (1·) and incubated for 60 min at 37 C in a moist chamber
with the TUNEL mix (0.3 U/lL calf thymus terminal deoxynucleotidyl
transferase, 7 pmol/lL biotin dUTP, and 1 mM cobalt chloride in 1·
reaction buﬀer in distilled water). After washing (four PBS baths of 5
min each at RT), the sections were saturated in 2% BSA for 10 min at
RT. Sections were treated for 30 min at 37 C in a moist chamber with
a 1:20 dilution of ExtraAvidin peroxidase antibody. After three PBS
washes, detection was performed with DAB [1.24 mg DAB, 25 lL of
3% NiCl2, and 152 lL of 1 M Tris–HCl (pH 7.5) in 2 ml distilled
water]. Slides were mounted in crystal mount (Biomeda, Foster City,
CA).
2.3. RT-PCR analysis
Total RNA was isolated from testes with Trizol and RT-PCR was
performed with the Gibco RT-PCR system. Denaturation was for 30 s
at 94 C, annealing for 30 s at 50–60 C, and synthesis for 1 min at 72 C.
The primers for each germ cell-speciﬁc marker are shown in Table 1.
2.4. Laser scanning cytometry (LSC)
Stained cells were analyzed on a three-color ﬂuorescence activated
cell sorter (FACScan; Becton-Dickinson Immunocytometry Systems,
San Jose, CA, USA) using CELL Quest software (Becton-Dickinson
Immunocytometry Systems). Dead cells and monocytes were excluded
by forward and side-scatter gating. An average of 20 000 events was
acquired depending on the cytokine studied. Statistical markers were
set using labeled isotype monoclonal antibody-blocked negative
controls as a reference.2.5. Apoptosis assay by ﬂow cytometry
Detection of apoptotic cells was based on the principle of Annexin V
binding to translocated plasma membrane phosphatidylserine (PS) as
previously described [44,45]. Brieﬂy, cells were washed, trypsinized,
pelleted, resuspended in staining buﬀer (10 mM HEPES/NaOH, pH
7.4, 140 mM NaCl, and 5 mM CaCl2) containing 1 lg/ml PI and 5 ll
Annexin V (BD PharMingen), and incubated for 15 min. The cell
mixture was then subjected to analysis by a ﬂow cytometer (FAC-
SCalibur, Becton-Dickinson). A minimum of 3 104 events was col-
lected for each sample. Analysis of the multivariate data was
performed with CELLQuest software (Becton-Dickinson).
2.6. Immunohistochemical analysis
Immunohistochemical staining was performed as previously de-
scribed, with slight modiﬁcations [10]. Tissue for immunostaining was
cleared in Histoclear for approximately 10 min and dehydrated in
decreasing concentrations of ethanol. Immunohistochemistry was
performed according to standard procedures provided by the manu-
facturer (Mouse, Rabbit and Rat UniTectTM Immunohistochemistry
System, Oncogene Science, Inc.). Sections were placed in 3% peroxide
in pure methanol and in 0.1% pepsin in 0.05 N HCl (pH 2.25) for 30
min each to reduce background staining. Sections were washed twice (5
min each) in TBS (0.05 M Tris–HCl, pH 7.4, and 0.85% NaCl),
blocked with normal horse serum diluted in TBS (1:5; NHS–TBS), and
incubated overnight with primary Rb (Pharmingen) and PCNA
(Pharmingen) antibodies diluted 1:250 in NHS–TBS. One drop of
horse serum was used as a negative control. Excess antibody was re-
moved by washing twice for 5 min with TBS, and then biotinylated
secondary IgG or IgG2a was added for 30 min, followed by washing
with three changes of TBS for 5 min. Color was developed with a
solution of 0.5% diaminobenzidine in 0.05 M Tris–HCl (pH 7.6)
containing 0.01% hydrogen peroxide, after which sections were washed
in water, dehydrated, and mounted with a coverslip.
2.7. Immunoblot analysis
Decapsulated testes from mice were snap-frozen in liquid nitrogen in
lysis buﬀer [50 mM Tris HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1
mM a-D-octylglucoside, 1 mM EDTA, 14 mM mercaptoethanol,
protease inhibitor cocktail (5 ll/0.1 g, Sigma), and 2 mM PMSF].
After sonication for 20 s, the lysates were cleared by centrifugation at
15 000 rpm for 15 min at 4 C. Protein extracts were analyzed by 7.5%
SDS-PAGE and electroblotted to PVDF membranes. Membranes
were treated with antibodies to Rb (Pharmigen, 1:100) or PCNA
(Pharmigen, 1:100) and FasL (Pharmigen, 1:100) followed by peroxi-
dase-conjugated anti-mouse IgG secondary antibody (1:25 000, Im-
munoTech). An anti-actin antibody (1:500; Chemicon International)
was used to verify equal protein loading. Signals were visualized using
an ECL kit (Amersham) and bands were quantiﬁed by densitometry
and image analysis using Image J 1.23 (NIH image).
2.8. Data analysis
All experimental data are presented as meansS.D. Each experi-
ment was performed at least three times and subjected to statistical
analysis. Representative experiments are presented in the Figures. For
statistical analysis, one-way analysis of variance (ANOVA) was per-
formed to determine whether there were diﬀerences among all groups
(P < 0:05), and Fisher’s post-test was performed to determine signiﬁ-
cance between pairs of groups. A P value below 0.05 was considered
signiﬁcant. Statistical tests were performed using StatView software
version 5.0 (SAS Institute Inc, Cary, NC).3. Results
3.1. Eﬀects of busulfan treatment on testicular weights and
histology
We initially investigated the eﬀects of busulfan on the whole
testis and on developing male germ cells, as visualized in sec-
tions of mouse testes. The body weight of both control and
busulfan-treated mice increased steadily from 8 to 12 weeks.
Testicular weight also increased steadily in control animals for
the duration of the experiment. In contrast, testis weight
Table 1
Primers and conditions used for semi-quantitative RT-PCR
Primer name Primer sequence PCR conditions Size (bp) Ref./GenBank
c-kit F: GCATCACCATCAAAAACGTG Tm: 58 C 332 NM021099
R: GATAGTCAGCGTCTCCTGGC 35 cycles
GLI 1 F: ACTGGGGTGAGTTCCCTTCT Tm: 61.5 C 357 [27]
R: GCTGAGCTTTGAGCTGTCCT 40 cycles
Odc F: CATCCAAAGGCAAAGTTGGT Tm: 60 C 393 NM013614
R: GCCTGGCTCAGCTATGATTC 30 cycles
Stra8 F: GCCAGAATGTATTCCGAGAA Tm: 57 C 650 [43]
R: CTCACTCTTGTCCAGGAAAC 29 cycles
P53 F: GGAGTATTTGGACGACCG Tm: 51 C 350 NM011640
R: TCAGTCTGAGTCAGGCCC 35 cycles
Prohibitin F: GTGGCGTACAGGACATTGTG Tm: 57 C 307 NM008831
R: AGCTCTCGCTGGGTAATCAA 30 cycles
SRF-1 F: TCCATTCAGCACCTTCAACA Tm: 60 C 304 [29]
R: TCATCCAAATGGAAAGAGCC 30 cycles
Mak F: TGGGAAGTATAATGGCCGAG Tm: 57 C 326 NM008547
R: TGCAGAAGAGCCCAGTACCT 30 cycles
Iba 1 F: CGATGATCCCAAATACAGCA Tm: 60 C 314 [31]
R: GACCAGTTGGCCTCTTGTGT 30 cycles
Bcl-2 F: TAAGCTGTCACAGAGGGGCT Tm: 65 C 344 NM009741
R: TGAAGAGTTCCTCCACCACC 30 cycles
Bax F: CGAGCTGATCAGAACCATCA Tm: 58 C 283 NM007527
R: GAAAAATGCCTTTCCCCTTC 30cycle
RAD51 F: GTTACCATACAGTGGAGGCTGT Tm: 60 C 665 NM011234
R: GGTGATTACCACTGCGACAC 30 cycles
TNFa R55 F: TGCTGCACCAAGTGCCACAAAG Tm: 57 C 325 [43]
R: CACACGGTGTTCTGAGTCTCC 25cycles
PCNA F: GCTGACATGGGACACTTA Tm: 59 C 160 NM011045
R: CTCAGGTACAAACTTGGTG 30cycles
Fas F: GAGAATTGCTGAAGACATGACAATCC Tm: 67 C 374 [43]
R: GTAGTTTTCACTCCAGACATTGTCC 35 cycles
FasL F: CTTAGCTTCTCTGGAGCAGTCAGCGTC Tm: 70 C 300 [43]
R: CCTTCTTCTTTAGAGGGGTCAGTGGC 35 cycles
GAPDH F: GTGAAGGTCGGTGTGAACGG Tm: 60 C 620 NM008084
R: GATGCAGGGATGATGTTCTG 30 cycles
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mencing in week 1 and reaching its lowest point four weeks
after busulfan injection (33% of control value) (Fig. 1A).
Testicular weight progressively recovered thereafter to reach
approximately 90% of control weight at 12 weeks. Four weeks
after the injection of a single dose of busulfan, male germ cells
were signiﬁcantly reduced in number, and most of the sper-
matogenic cells except spermatogonia were absent (Fig. 1B). In
contrast, at all time-points investigated, somatic cells, includ-
ing Sertoli and Leydig cells, appeared normal in size, shape
and localization, but their numbers were slightly reduced by
busulfan treatment (data not shown).
3.2. Identiﬁcation of apoptotic cells by TUNEL assay following
busulfan treatment
We previously demonstrated that busulfan treatment in-
duces apoptosis in male germ cells in a dose- and time-
dependent manner [10,11]. Busulfan was administered at the
rate of 40 mg/kg body weight to induce a maximal number ofapoptotic cells while minimizing the number of necrotic cells.
Testicular cell apoptosis and necrosis were analyzed by ﬂow
cytometry. Exposure of mice to a single dose of busulfan
caused a signiﬁcant increase in the percentage of apoptotic
cells (P < 0:05) in a time-dependent manner, as assessed by
Annexin V-FITC staining (Fig. 2B).
Very few TUNEL-positive cells were detected in the testes of
control adult mice and most of these were spermatocytes.
However, a marked increase in the frequency of TUNEL-po-
sitive cells was observed in testis sections from mice sacriﬁced
one week after busulfan treatment (Fig. 2A, and week 1 of
Fig. 2B). This eﬀect peaked at week 2 and then decreased
gradually, with the number of TUNEL-positive cells reaching
normal control levels by four weeks (Fig. 2B). One week fol-
lowing busulfan treatment, most TUNEL-positive germ cells
were spermatogonia and a few were spermatocytes (Fig. 2A,
week 1). Two to three weeks post-treatment, a marked cell-
speciﬁc increase in apoptosis was observed in meiotic sper-
matocytes (Fig. 2A, weeks 2 and 3). At four weeks, testes from
Fig. 1. Photomicrographs of cross-sections from mouse testis. (A) Body and testis weights four and six weeks after busulfan treatment. (B) His-
tological analysis of testis sections from 12-week-old control and busulfan-treated mice. Dewaxed paraﬃn sections were stained in hematoxylin and
eosin. Four weeks after busulfan treatment, the testes of most busulfan-treated mice are depleted in germ cells although they contain somatic cells
and spermatogonia. Magniﬁcation: 200.
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germ cells, with the exception of some undiﬀerentiated sper-
matogonial stem cells (Fig. 2A, week 4). During weeks 5 and 6,
more diﬀerentiated germ cells began to appear, including
pachytene cells and early spermatocytes (data not shown). This
observation indicates that undiﬀerentiated spermatogonial
germ cells are more resistant than diﬀerentiated spermatogonia
to busulfan toxicity and that the re-appearance of spermato-
cytes in busulfan-treated testes is due to the proliferation and
diﬀerentiation of surviving spermatogonial stem cells.
3.3. RT-PCR analysis of male germ cell-speciﬁc marker genes
To determine which cell types are sensitive to busulfan-in-
duced apoptosis, we performed RT-PCR for germ cell-speciﬁc
markers (Table 1 and Fig. 3). At week 1 post-treatment, c-kit
and Stra 8 expression was signiﬁcantly decreased (Fig. 3A,
panel a). However, Gli-1, which is more highly expressed in
type B spermatogonia, was expressed at constant levels in the
busulfan-treated testis (Fig. 3B). Since c-kit is involved in the
survival of pre-meiotic germ cells, it is possible that apoptosis
triggered by busulfan might be related to the decreased ex-
pression of this growth factor receptor. This would suggest
that c-kit-expressing type A spermatogonia are more sensitive
to busulfan-induced damage and that germ cell apoptosis is
controlled in a cell type-speciﬁc fashion. One to two weeks
after busulfan treatment, Rad51 mRNA decreased slightly,
and by three weeks the level of transcript was signiﬁcantly
reduced (Fig. 3A, panel b, and Fig. 3B). However, the level of
prohibitin mRNA increased from one to three weeks but de-
creased after four weeks (Fig. 3B). These results suggest that
pachytene spermatocytes are also sensitive to busulfan and
that apoptosis follows spermatogonial degeneration. The tes-
ticular expression of FasL, Iba I and TGF bRI mRNA re-
mained constant for three weeks after busulfan treatment and
then decreased at four weeks (Fig. 3B). This observation in-
dicates that haploid germ cells had completely disappeared ordied and that a third wave of apoptosis induced by busulfan
involves post-meiotic spermatids.
3.4. Depletion of male germ cells is mediated by a FasL/
Fas- and p53-independent pathway
It is well known that the p53 and FasL/Fas systems regulate
apoptosis in germ cells [14,19]. To determine whether busulfan
kills testicular germ cells through an apoptotic pathway, we
performed Western blot analysis. As shown in Fig. 5, p53 and
Bax protein expression was not aﬀected by busulfan treatment.
Next, we analyzed FasL and Fas protein expression levels after
busulfan treatment (Fig. 5). FasL and Fas protein expression
were not modiﬁed during weeks 1–3 despite the depletion of
pre-meiotic germ cells that express Fas. Since the DNA-dam-
aging agent busulfan did not result in an increased level of p53
and FasL/Fas mRNA and protein during the period of germ
cell death, this result suggests that germ cell apoptosis can
occur independently of p53 and FasL/Fas (Fig. 5).
3.5. Busulfan-induced hypophosphorylation of Rb prevents
apoptosis of spermatogonial stem cells by inhibiting
PCNA expression
Four to six weeks after busulfan injection, testis weights
were signiﬁcantly reduced and most spermatogenic cells were
depleted. Approximately 1.5 0.8 106 (n ¼ 5) cells per testis
were recovered from busulfan-treated mice, which is about
3.5% of the cells in a normal testis (4.3 0.9 107, n ¼ 5). To
identify the point in the cell cycle at which busulfan acts, we
used ﬂow cytometric analysis. Testicular cells were divided into
three groups (1n, 2n, 4n) based on DNA content as assessed by
PI labeling intensity (Fig. 4A). Diploid spermatogonia and
somatic cells fell into the 2n group. Busulfan administration
resulted in a gradual increase in the frequency of 2n cells,
which corresponds to the G0/G1 phase (Fig. 4B), whereas the
number of cells in S (1n) and/or G2 + M (4n) was signiﬁcantly
reduced depending on the time after busulfan treatment. At
Fig. 2. Monitoring of male germ cell apoptosis following busulfan treatment by the TUNEL and annexin V assays. For assay details, see Section 2.
(A) TUNEL analysis of sections prepared from one to four weeks after busulfan treatment. Male germ cell apoptosis is indicated by brown col-
oration. One week after treatment, apoptotic cells are limited to spermatogonia, but at two to four weeks, they include meiotic to postmeiotic germ
cells. Arrows on the 1, 2, and 3 weeks panels indicate apoptotic male germ cells; arrow on the 4 weeks panel indicates a surviving spermatogonial cell.
ST, seminiferous tubule. (B) A representative analysis of apoptotic cells in busulfan-treated testes as detected by Annexin V staining. Male germ cells
were selected on a laminin-coated dish. and then fractionated into Annexin V-positive (apoptotic) subpopulations. The distributions of apoptotic
subpopulations are shown for cells assayed with the secondary IgG alone (negative control), control cells, and cells 1, 2, 3, and 4 weeks after busulfan
treatment. The frequency of Annexin 5-positive cells increases one week after busulfan treatment, peaks at week 3, and drops rapidly to control levels
at four weeks.
Y.-J. Choi et al. / FEBS Letters 575 (2004) 41–51 45four weeks, these cells were undetectable (Fig. 4A, panel 4
week).
Immunohistochemical analysis of normal adult (Fig. 6A,
panel b) and postnatal day 5 (Fig. 6A, panel a) testes revealed
extensive PCNA-positive staining in all seminiferous tubules.
However, 66% (97/147) of the seminiferous tubules in busul-
fan-treated mice were negative for PCNA, with only a few
tubules weakly staining (Fig. 6A, panel c). To determine the
mechanism by which busulfan restricts spermatogonial pro-
liferation, we proﬁled pRB, a phosphoprotein that controls the
expression of genes necessary for progression through the cell
cycle. Testes of busulfan-treated mice showed a higher level of
pRB expression (Fig. 6A, panel f), whereas control adult testis
showed very low levels of expression (Fig. 6A, panel e), and
postnatal day 5 testes exhibited intermediate levels of pRb
(Fig. 6A, panel d). Consistent with this view, Rb phosphory-
lation (Fig. 6C, busulfan) and PCNA expression (Fig. 6B) were
inhibited in the bulsufan-treated testis, compared to that of
adults or neonates (Fig. 6C and B). The hypophosphorylated
form of p110Rb has been found to complex with the cellulartranscription factor E2F. Thus, busulfan-induced hypo-
phosphorylation causes p110Rb to remain bound to E2F,
thereby maintaining E2F in an inactive form that cannot
promote transcription of the PCNA gene (Fig. 8). Therefore,
we examined the inhibitory eﬀects of busulfan on cdk2, cdk4,
cyclin D1, and cyclin E expression using RT-PCR (Fig. 7).
Busulfan inhibited cdk2 and 4 as well as cyclin E, but not
cyclin D transcripts, indicating that it is a speciﬁc inhibitor of
cdk/cyclin complexes. Through this pathway, busulfan may
prevent apoptosis in spermatogonial stem cells by inhibiting
the expression of proteins critical for G1 progression, such as
PCNA.4. Discussion
This study revealed that busulfan treatment results in germ
cell damage and that germ cell apoptosis mediated by loss of
the c-kit/SCF pathway is independent of p53 or Fas/FasL.
In experimentally induced cryptorchid animals, pre-meiotic
Fig. 3. Male germ cell-speciﬁc gene expression levels in busulfan-
treated adult testis. (A) RT-PCR analysis. (a) A representative analysis
of spermatogonia-speciﬁc markers. c-kit is expressed mainly from type
A to early meiotic stages, and Stra 8 is expressed mainly in type A
spermatogonia. Both OCD and Gli-1 mRNA are expressed in type B
and early spermatocytes, including type B spermatogonia. (b) Analysis
of meiotic germ cell-speciﬁc markers. Rad51is expressed mainly in
pachytene stage spermatocytes, but prohibitin and SRF are expressed
mainly in leptotene spermatocytes. (c) Analysis of haploid-speciﬁc
markers. FasL and Iba I are expressed mainly in round and elongated
spermatids. (d) Analysis of apoptosis related markers. Apoptosis in
male germ cells is mediated by a P53 and/or FasL/Fas-independent
pathway. (B) Densitometric analysis of the RT-PCR results shown in
(A). Values are shown relative to the highest value, which was nor-
malized to 100% (P < 0:05). The time points are indicated at bottom.
c-kit and Stra8 mRNA are lost one week following busulfan treatment,
whereas Rad51 mRNA is lost at week 2 and prohibitin and SRF are
reduced from 3 weeks onward. FasL and Iba I are lost at week 4, but
Fas mRNA and Bax are constantly expressed.
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spermatids are more sensitive to testicular heat stress [19,24].
Round spermatids are exquisitely sensitive to alkylating agents
such as cyclophosphamide [23,25]. Since the precise molecular
target of alkylating agents diﬀers according to their chemical
structure, it is possible that the biological eﬀects and target(s)
of busulfan are diﬀerent from those of cyclophosphamide.
Previous studies [16–19,25,37] suggested that diﬀerent sper-
matogenic cell types exhibit remarkable variation in their
susceptibility to stressful stimuli and that several apoptotic
pathways are activated during male germ cell diﬀerentiation in
response to diﬀerent stress conditions.
We analyzed the mRNA levels of the pre-meiotic markers
c-kit, Stra8, Gli-1, and Gli-3 [26,27], the meiotic markers
prohibitin, PCNA, SRF, Mak, and Rad51 [28–30] and the
post-meiotic markers FasL, TGF betaRI, and Iba [31,32]. In
the adult testis, the c-kit receptor is expressed in diﬀerentiating
spermatogonia but not in spermatogonial stem cells. However,
SCF is expressed in Sertoli cells [33]. Stra8 is a retinoic acid-
inducible gene which is expressed in all spermatogonia and it is
present at the highest levels in preleptotene spermatocytes [26].
Therefore, c-kit, Gli-1, and Stra8 mRNA were examined to
determine the relationship between susceptibility to busulfan-
induced apoptosis and spermatogonial cell types (Fig. 3). At
week 1 post-treatment, c-kit expression was reduced to unde-
tectable levels. Notably, this decrease in c-kit expression oc-
curred earlier than the increase in TUNEL-positive cells. The
expression of other spermatogonial markers also decreased,
albeit with diﬀerent kinetic patterns as compared to c-kit. The
decrease in Stra8 mRNA levels in the busulfan-treated testis
was accompanied by an increase in TUNEL-positive cells.
Thus, downregulation of c-kit mRNA levels appears to reﬂect
a cellular response to busulfan treatment, whereas reduced
Stra8 gene expression is closely associated with an enhance-
ment of busulfan-induced death in diﬀerentiating spermato-
gonial cells and preleptotene spermatocytes. During this time,
however, p53, Bax and Bcl-2 mRNA expression was not re-
duced. Therefore, the premature termination of spermato-
genesis was accompanied by increased apoptosis, which must
be due to loss of a survival factor such as c-kit. Although
diﬀerentiating spermatogonia from busulfan-treated testes
were repopulated from the surviving spermatogonial stem
cells, Stra8 gene expression was consistently downregulated
until six weeks after busulfan treatment, indicating that the
Stra8 function is not important for spermatogonial diﬀerenti-
ation but that it is essential for preleptotene spermatocytes.
In the mouse testis, TNFa R55 is expressed in Leydig cells
and Sertoli cells, but SCF is exclusively produced in Sertoli
cells [33]. A slight, albeit signiﬁcant, decrease in TNFa R55
and SCF mRNA levels was observed one to three weeks after
busulfan treatment, but the expression of both increased from
week 4 onward and reached maximal levels at four to six weeks
(Fig. 3). This observation indicates that somatic cells were not
damaged by busulfan treatment and that busulfan is not toxic
for Sertoli cells. Given that TNFa R55 is a receptor that reg-
ulates diﬀerentiated functions of testicular cells and that SCF
is a spermatogonial survival factor [33], their increased ex-
pression four weeks after busulfan treatment suggests that
these factors might induce DNA repair or the resumption of
spermatogonial stem cell proliferation after chemotherapy.
Also, four weeks after busulfan treatment, c-kit expression was
detectable, and it was restored to control levels at ﬁve weeks.This result suggests that mitotic proliferation resumed and that
proliferating type A spermatogonia reappeared in some semi-
niferous tubules four weeks after busulfan treatment. It also
indicates that the c-kit/SCF pathway is critical for male germ
cell survival and that busulfan treatment results in transient,
rather than permanent, infertility due to the downregulation of
c-kit expression.
The second wave of apoptosis induced by busulfan treat-
ment aﬀected meiotic spermatocytes. It is well known that
pachytene spermatocytes express high levels of RAD51 and
that transcript decreases to nearly undetectable levels in
elongating spermatids, whereas PCNA is expressed at various
stages of spermatocyte development from pachytene sperma-
tocytes to round spermatids [24]. It is also postulated that
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Y.-J. Choi et al. / FEBS Letters 575 (2004) 41–51 47PCNA and RAD51 may be involved in excision repair up to
mid-spermatogenesis. Mak mRNA intensely localizes in late
pachytene (stage X) and diplotene (stage XI) spermatocytes,
and immunostains weakly in dividing spermatocytes (stage
XII) and early round spermatids (stages I–II) [29]. However, a
recent study showed that Mak= mice develop normally and
without gross abnormalities [34], indicating that Mak function
is not essential for spermatogenesis and male fertility. Al-
though PCNA mRNA remained constant after busulfan
treatment, the busulfan-treated testis exhibited decreased ex-
pression of prohibitin, Stra8, Mak mRNAs, and RAD51,
which are involved in DNA damage repair. Therefore, it is
plausible that preleptotene spermatocytes and pachytene
spermatocytes are more sensitive to stress stimuli, such as
busulfan treatment, relative to mid-spermatocytes and that
some busulfan-induced damage in these cells might be caused
by the loss of mediators of DNA repair such as RAD51.
Alessio et al. [31] demonstrated that FasL mRNA is pre-
dominantly expressed in round spermatids and to a lesser ex-
tent in pachytene spermatocytes in mouse and rat testis,
whereas only the protein is expressed in mature spermatozoa.
Iba I mRNA appeared to be expressed in spermatids at steps
1–12 and Iba I protein were detectable at steps 10–19 [32].
However, FasL, Iba I, and TGFb RI mRNA in busulfan-
treated mice, as compared to control adult mouse testis, was
constantly expressed for three weeks and then rapidly reduced
from four weeks (Fig. 3). Although Iba I expression, compared
to FasL and TGFb RI, was reduced during this time, Iba I was
expressed at somewhat higher levels, indicating that a thirdwave of apoptosis induced by busulfan treatment aﬀects round
spermatids rather than elongated spermatids. Taken together,
our observations support the report by D’Alessio et al. [31]
that FasL is expressed in male germ cells but not in Sertoli
cells. However, Fas mRNA was constantly expressed even
after germ cell loss. Therefore, the long-term adverse biological
eﬀects of Fas mRNA expression after busulfan treatment must
be further investigated.
Jordan et al. [35] previously demonstrated that spermato-
genesis in Wv/Wv (c-kit receptor deﬁcient) mice can be rescued
by loss of the p53 gene. However, a more recent study has
shown that the loss of the p53 function does not promote or
rescue spermatogenesis in Sl/Sld mutant testes, indicating that
germ cell deﬁciency in the c-kit/SCF mutant is not dependent
on p53-mediated apoptosis [36]. We observed TUNEL-posi-
tive germ cells in diﬀerentiated spermatogonia and meiotic
male germ cells of the busulfan-treated testis (Fig. 2A). RT-
PCR analysis showed that the busulfan-treated testis lacked
male germ cells, as evidenced by c-kit expression (Fig. 3). In
addition, it exhibited a low but constant level of p53 mRNA
(Figs. 3 and 5). This result, coupled with a previous observa-
tion [37], suggests that DNA-damaging agents do not result in
increased levels of p53 mRNA and that the half-life of the p53
protein is prolonged in the testis of the busulfan-treated
mouse. Therefore, the fact that p53 protein expression did not
correlate with mRNA levels might reﬂect the autoregulatory
control of p53 expression, because the protein binds to and
inhibits the translation of its own mRNA [37]. In this study, it
is notable that the apoptotic mechanisms in male germ cells
Fig. 4. A representative ﬂow cytometric analysis of surviving testicular cells after injection of a single dose of busulfan. (A) Time course analysis
reveals that the percentages of both haploid and G2/M cells, which consist of primary spermatocytes, decrease over time as compared to control
testicular cells, and reaches a minimum four weeks after busulfan treatment. No further decrease occurs and the cell cycle resumes at ﬁve weeks. (B)
This observation was reanalyzed with respect to germ cell stages. The percentages of 1n (postmeiotic) and 4n (meiotic) germ cells are signiﬁcantly
lower in busulfan-treated testes than in control testes at all timepoints, whereas 2n (somatic and premeiotic germ) cells slightly increase in frequency,
peaking at four weeks, compared to control testes, indicating that spermatogonia and somatic cells are not damaged by busulfan treatment.
48 Y.-J. Choi et al. / FEBS Letters 575 (2004) 41–51exposed to busulfan are quite distinct from those triggered by
X ray exposure or seen in the cryptorchid-induced testis and
c-kit receptor-deﬁcient mice. Our results suggest that the lossFig. 5. Western blot analysis of the FasL/Fas- and p53-independent
pathways. P53, Bax, Fas, and FasL protein expression are unchanged
one to three weeks after busulfan treatment. At four weeks, p53 and
Fas expression slightly increases, but Bax and FasL expression is re-
duced, indicating that male germ cell apoptosis after busulfan treat-
ment does not occur via the p53 or Fas/FasL pathways.of c-kit/SCF signaling results in busulfan-induced male germ
cell death.
In vivo spermatogonial growth is regulated by the degree to
which stem cells in basal seminiferous tubules remain in the
quiescent (G0) or proliferative (S/G2/M) phases of the cell
cycle. This process is aberrant in the testis of the busulfan-
treated mouse. Spermatogonial hyperproliferation in the
busulfan-treated mouse testis is characterized by a markedly
increased percentage of normally quiescent spermatogonial
stem cells in the proliferative phases of the cell cycle (Fig. 4A).
The data presented here indicate that busulfan does not aﬀect
stem cells. As shown in Fig. 8, busulfan acts after cyclin E
induction, but prior to PCNA expression and DNA synthesis,
in developing male germ cells. Although PCNA expression was
markedly reduced, it was not completely abolished by busulfan
treatment (Fig. 6). To determine if the degree of PCNA re-
duction was associated with a failure to progress into DNA
synthesis per se (S/G2/M), mice were treated with busulfan and
their testicular cells were analyzed by ﬂow cytometry. This
experiment indicated that the G1 block results from the bu-
sulfan-induced inhibition of PCNA synthesis. However,
PCNA expression was higher in control adult and postnatal
day 5 testes than in the busulfan-treated testis.
Rb is present in an unphosphorylated form, which hinders
the transition from G1 to S phase, and in a phosphorylated
form, which induces cell-cycle progression [38]. The active
Fig. 6. Localization of Rb and PCNA expression in control adult, postnatal day 5, and busulfan-treated testis. (A) PCNA is very strongly expressed in
control and postnatal day 5 testes but is expressed at reduced levels in busulfan-treated testis. Although Rb expression is almost undetectable in the
control adult testis, it increases after busulfan treatment and peaks at four weeks. However, postnatal day 5 testis shows a moderate level of Rb
expression. (B and C) Western blot analysis of PCNA and pRB/ppRB expression, respectively. pRB and ppRB are expressed at equal levels in
postnatal day 5 testis (neonate in C). Busulfan-treated testis exhibits strong pRB (busulfan in C) and weak PCNA signals (busulfan in B), but control
adult testis exhibits strong ppRB (adult in C) and PCNA signals (adult in B). pRB, the hypophosphorylated form of Rb; ppRB, the hyper-phos-
phorylated form.
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Fig. 7. RT-PCR analysis of cell cycle-speciﬁc gene expression levels in busulfan-treated adult testis from week 0 to week 6. Timepoints are indicated
at bottom. Temporal changes in expression levels were plotted based on densitometric analysis of RT-PCR. Values are shown relative to the highest
value, which was normalized to 100 percent (P < 0:05). (A, B, C and D) show RT-PCR analyses of CDK4, cyclin D1, CDK2, and cyclin E,
respectively. The expression of cdk4, cdk2 and cyclin E mRNA is slowly reduced, whereas cyclin D1 is not aﬀected.
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50 Y.-J. Choi et al. / FEBS Letters 575 (2004) 41–51form (pRB) is primarily found in resting cells, whereas the
hyperphosphorylated form (ppRB) is primarily found in pro-
liferating cells. Previous studies of Rb in mammalian testes did
not distinguish between the two forms [39,40]. In this study, we
used the G3-245 antibody to distinguish between the two
forms. In the control adult testes, pRB staining was negative in
most cells, including germ cells and somatic cells, and a few
spermatogonia located along the basement membrane were
stained (e of Fig. 6A), whereas moderate levels of expression
could be detected in spermatogonia of postnatal day 5 testes (d
of Fig. 6A). However, testes of busulfan-treated mice stained
more intensely for pRB (Fig. 6A, panel f). This observation
agrees with the results of Western blot analysis (Fig. 6C).
Therefore, the upregulation of Rb expression in the busulfan-
treated testis is likely to be induced by its eﬀects on
spermatogonial germ cells. According to this concept, we hy-
pothesize that RB phosphorylation is normally repressed in
resting spematogonial stem cells after busulfan treatment and
that it is de-repressed for normal spermatogenesis after loss of
busulfan activity (Fig. 8). Given the its established role in
protection against cell death [41], pRB reduces but does not
eliminate apoptosis in actively developing male germ cells.
However, moderate RB expression and high PCNA expression
in the postnatal day 5 testis indicate that it contains actively
dividing spermatogonia rather than resting spermatogonial
stem cells, explaining why neonatal spermatogonia are less
able to colonize a recipient testis than are adult stem cells [42].
To our knowledge, this is the ﬁrst report showing evidence for
the survival of spermatogonial stem cells after busulfan treat-
ment, which can be directly related to protection of male germ
cells from cell death.
In view of the increased usage of high dose chemotherapy
with autologous or allogeneic stem cell transplantation and appp
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Fig. 8. Schematic depicting the survival of spermatogonial stem cells
following busulfan treatment. The active form of Rb (pRB) is pri-
marily found in resting cells, whereas the hyperphosphorylated form
(ppRB) is primarily found in proliferating cells. Testes of busulfan-
treated mice show a higher level of pRB expression, whereas control
adult testis shows a very high level of ppRB expression. Therefore,
bulsufan treatment may inhibit Rb phosphorylation in the testis via the
inhibition of cyclin E. In its hypophosphorylated form, p110Rb re-
mains bound to E2F, which in the complexed form is inactive and
cannot transcribe the PCNA gene. Therefore, spermatogonial stem
cells may be protected from cell death by cell cycle arrest at G0/G1.gradually increased cure rate of patients that have undergone
such therapy, the prospect of young patients maturing and
establishing families is increasing. A large fraction of such
patients are, however, infertile because of the previous high
dose therapy [21]. The basis for understanding how to address
this problem starts with understanding the molecular mecha-
nisms underlying the infertility. In this study, these questions
were addressed in an experimental setting in the present
studies. In conclusion, we observe that (1) the loss of sper-
matogonia through apoptosis is mediated by c-kit, and (2) this
loss is not associated with changes in the expression of P53,
Bax or Bcl-2 protein, and (3) the survival of spermatogonia
stem cells is mediated by the cell cycle.
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